| Autor: |
Fazli S; Department of Occupational Health., Thomas A; Oregon National Primate Research Center, Division of Neuroscience, and., Estrada AE; Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon, USA., Ross HA; UCLA, Los Angeles, California, USA., Xthona Lee D; Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon, USA., Kazmierczak S; Department of Pathology, Oregon Health & Science University, Portland, Oregon, USA., Slifka MK; Oregon National Primate Research Center, Division of Neuroscience, and., Montefiori D; Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA., Messer WB; Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon, USA.; Department of Medicine, Division of Infectious Diseases, Oregon Health & Science University, Portland, Oregon, USA.; Program in Epidemiology, Oregon Health & Science University, Portland State University School of Public Health, Portland, Oregon, USA., Curlin ME; Department of Occupational Health.; Department of Medicine, Division of Infectious Diseases, Oregon Health & Science University, Portland, Oregon, USA.; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, USA. |
| Abstrakt: |
BACKGROUNDVaccination is typically administered without regard to site of prior vaccination, but this factor may substantially affect downstream immune responses.METHODSWe assessed serological responses to initial COVID-19 vaccination in baseline seronegative adults who received second-dose boosters in the ipsilateral or contralateral arm relative to initial vaccination. We measured serum SARS-CoV-2 spike-specific Ig, receptor-binding domain-specific (RBD-specific) IgG, SARS-CoV-2 nucleocapsid-specific IgG, and neutralizing antibody titers against SARS-CoV-2.D614G (early strain) and SARS-CoV-2.B.1.1.529 (Omicron) at approximately 0.6, 8, and 14 months after boosting.RESULTSIn 947 individuals, contralateral boosting was associated with higher spike-specific serum Ig, and this effect increased over time, from a 1.1-fold to a 1.4-fold increase by 14 months (P < 0.001). A similar pattern was seen for RBD-specific IgG. Among 54 pairs matched for age, sex, and relevant time intervals, arm groups had similar antibody levels at study visit 2 (W2), but contralateral boosting resulted in significantly higher binding and neutralizing antibody titers at W3 and W4, with progressive increase over time, ranging from 1.3-fold (total Ig, P = 0.007) to 4.0-fold (pseudovirus neutralization to B.1.1.529, P < 0.001).CONCLUSIONSIn previously unexposed adults receiving an initial vaccine series with the BNT162b2 mRNA COVID-19 vaccine, contralateral boosting substantially increases antibody magnitude and breadth at times beyond 3 weeks after vaccination. This effect should be considered during arm selection in the context of multidose vaccine regimens.FUNDINGM.J. Murdock Charitable Trust, OHSU Foundation, NIH. |
